Angiocentric glioma is a rare brain tumor that usually starts in childhood or young adulthood. People with angiocentric glioma often have seizures that may be hard to control at first. The tumor tends to grow slowly, and symptoms can build over months to years. Surgery is the main treatment, and many people do well when the tumor can be fully removed. The risk of death is low compared with aggressive brain cancers, but follow-up imaging and seizure care are important.
Overview
Angiocentric gliomaSymptoms
Angiocentric glioma often shows up with seizures, usually focal and hard to control. Other early symptoms of angiocentric glioma can include headaches, trouble with memory or schoolwork, and weakness or tingling on one side. Symptoms vary by tumor location.
Outlook and prognosis
Many living with angiocentric glioma do well after surgery, especially when the tumor can be fully removed. Seizures often improve, and long-term control is common. Recurrence is uncommon but possible, so periodic MRI follow-up helps catch changes early.
Causes and risk factors
Angiocentric glioma usually arises from a tumor-specific genetic change, most often a MYB–QKI fusion, that occurs after conception and isn’t inherited. Established risk factors are unknown; it mainly affects children and adolescents, with no proven environmental or lifestyle triggers.
Genetic influences
Genetics play a central role in angiocentric glioma. Most tumors carry somatic MYB gene alterations that drive growth; these are not inherited. Germline predisposition is rare, so family members typically don’t have increased risk.
Diagnosis
Doctors suspect Angiocentric glioma based on seizures, neurological exam, and brain MRI showing a cortex-based lesion. The diagnosis of Angiocentric glioma is confirmed by surgical pathology from resection/biopsy, often with molecular testing to identify characteristic changes.
Treatment and drugs
Treatment for angiocentric glioma focuses on complete surgical removal when safely possible, which often controls seizures and lowers the chance of return. If full removal isn’t feasible, options can include anti‑seizure medicines and carefully planned reoperation or radiotherapy.
Symptoms
Seizure spells, headaches, or changes in thinking are common ways Angiocentric glioma shows up in daily life. Early symptoms of Angiocentric glioma may include brief staring spells or jerking episodes, headaches, or nausea, depending on where the tumor sits. Symptoms vary from person to person and can change over time.
These can look like brief staring spells, lip smacking, or jerking of one arm or leg. In Angiocentric glioma, seizures are often the first sign and may continue until the tumor is treated.
Headaches can be persistent or new for you. In Angiocentric glioma, they can feel worse in the morning or with coughing, bending, or straining.
Feeling sick to your stomach or throwing up can accompany headaches. This can happen if the tumor increases pressure in the brain.
You may notice forgetfulness, trouble focusing, or slower processing. Teachers, coworkers, or family may see schoolwork or job tasks take longer.
How people usually first notice Angiocentric glioma?
Many people first notice angiocentric glioma when seizures begin, often in childhood or adolescence, sometimes after a period of brief staring spells or unusual movements that were easy to overlook. Doctors are usually alerted by new-onset focal seizures and confirm suspicion with brain MRI, which typically shows a slow-growing lesion in the cerebral cortex. Because this tumor tends to be indolent, other symptoms like headaches or subtle changes in school performance may be mild at first, so “first signs of angiocentric glioma” are most commonly seizure-related.
Types of Angiocentric glioma
Angiocentric glioma is a rare brain tumor, most often found in children and young adults, that tends to grow slowly and cause seizures. Clinicians often describe them in these categories: based on how they look under the microscope, genetic changes in the tumor, and how they appear on brain scans. These variants can overlap, but they help explain why some people have earlier seizures or different MRI patterns. If you’re reading about types of angiocentric glioma, you’ll see that most share a core genetic change but can still behave a bit differently.
Classic histology
The tumor cells form sleeves around small blood vessels and often show a mix of spindled and ependymal‑like cells. This pattern is linked to long‑standing focal seizures and a slow pace of growth. On exam, doctors may see a well‑defined lesion with low cell division.
MYB‑altered
Most angiocentric gliomas carry changes in the MYB gene that act like a dimmer switch turned up, driving growth. People often present in childhood or adolescence with drug‑resistant seizures. Tumors with MYB fusions generally behave indolently and respond well to surgery.
MYBL1‑altered
A smaller subset shows changes in the related MYBL1 gene instead of MYB. Symptoms mirror the MYB group, with seizures as the main feature and few other neurologic changes. Outcomes after complete removal are typically favorable.
Temporal lobe–predominant
Many tumors arise in the temporal lobe, where they can trigger déjà vu, rising stomach sensations, or brief staring spells. MRI often shows a cortically based lesion with a T2‑bright, non‑enhancing look. Seizure control is often good after targeted surgery.
Extratemporal location
Less often, tumors occur in frontal, parietal, or occipital regions and may cause symptoms tied to that area, such as speech pauses or visual auras. Imaging can resemble the temporal pattern but with location‑specific features. Seizure types and cognitive effects vary with the brain region involved.
Pediatric onset
Most cases begin in school‑age children or teens, often with early morning or activity‑triggered focal seizures. Development is usually normal apart from seizure impact. Long‑term outlook is strong when the lesion is fully removed.
Adult onset
A minority present in adulthood, sometimes after years of subtle episodes mistaken for anxiety or migraines. Seizures may be less frequent but still focal, and tumors remain slow‑growing. Surgical outcomes remain favorable, though diagnosis can be delayed.
What genetics can tell you about symptoms
Some people with angiocentric glioma who carry MYB or MYBL1 gene fusions tend to have seizures starting in childhood or adolescence, often as the first sign. These fusions act like a stuck “on” switch for cell growth, driving a slow-growing, seizure‑prone tumor.
Causes and risk factors
Angiocentric glioma usually begins when a brain cell acquires a growth-driving genetic change. In many cases this involves the MYB gene, sometimes fused with a nearby gene called QKI, and it arises only in the tumor cells. It is not inherited and does not appear to run in families. There are no confirmed environmental or lifestyle risk factors for angiocentric glioma, and it is most often found in children and young adults. Knowing the risks can help you feel more in control.
Environmental and biological risk factors
Angiocentric glioma is a rare brain tumor seen mainly in children and young adults. Doctors often group risks into internal (biological) and external (environmental). For this tumor, clear risk factors are limited, but a few patterns stand out.
Most angiocentric gliomas are diagnosed in childhood or adolescence. Cases in older adults are uncommon. This age pattern suggests a biological window of vulnerability during brain development.
Radiation therapy to the head increases the chance of several brain tumors later on. A direct link to angiocentric glioma hasn’t been proven, but prior high-dose exposure is considered a general environmental risk for brain tissue. Medical imaging uses much lower doses and is not the same as therapeutic radiation.
Genetic risk factors
In angiocentric glioma, the key changes are genetic events inside the tumor itself, not traits you’re born with. The most consistent finding joins two genes, MYB and QKI, which turns on growth signals and weakens a natural brake. Science continues to uncover how these elements interact. Tumor DNA testing can sometimes confirm the diagnosis early when doctors are evaluating early symptoms of Angiocentric glioma.
MYB-QKI fusion: In most angiocentric gliomas, pieces of the MYB and QKI genes join together inside tumor cells. This fusion acts like a stuck-on growth switch and also reduces QKI’s normal braking function. It is considered the main genetic trigger for this tumor.
MYB activation: Even when tests do not detect the classic fusion, other changes can ramp up MYB activity. These changes push cells to divide and survive longer than they should.
QKI disruption: QKI normally helps brain support cells mature and keeps growth in check. When QKI is cut or fused, that balancing role is weakened, which supports tumor growth.
Chromosome 6q change: The MYB and QKI genes sit near each other on chromosome 6, and small DNA breaks or deletions there can bring them together. This reshuffling happens within tumor cells after conception, not across the whole body.
Somatic, not inherited: Some risk factors are inherited through our genes, but this tumor’s genetic changes are usually acquired only in the tumor. That means they are not passed down in families. Family members typically do not have a higher chance of angiocentric glioma because of this change.
No known syndromes: Unlike some brain tumors, angiocentric glioma has not been strongly linked to a hereditary cancer syndrome. Unless other red flags are present, a family tendency is unlikely.
Few other changes: Beyond the MYB-QKI change, these tumors often carry few additional genetic alterations. This pattern supports a single, central event rather than many inherited risks.
Lifestyle risk factors
Angiocentric glioma is driven by tumor-specific genetic changes, not by lifestyle habits. There are no proven lifestyle risk factors for Angiocentric glioma, but daily habits can influence seizure control, fatigue, and recovery after treatment. The points below explain how lifestyle affects Angiocentric glioma symptoms and complications in practical ways.
Consistent, adequate sleep helps stabilize seizure threshold in people with Angiocentric glioma–related epilepsy. Short or irregular sleep can increase seizures and worsen attention, mood, and daytime fatigue.
Taking anti-seizure medicines and any prescribed steroids or adjuvant drugs exactly as directed improves seizure control and reduces emergency visits. Skipped doses or abrupt changes can trigger breakthrough seizures and symptom flares.
High stress and anxiety can lower seizure threshold and intensify headaches. Relaxation techniques, counseling, or biofeedback may reduce seizure frequency and improve coping with symptoms.
Light-to-moderate activity can improve cognition, mood, and sleep in people living with a brain tumor. Avoid contact sports or high-impact activities if you have recent surgery, balance issues, or signs of raised intracranial pressure.
Risk prevention
There’s no known way to prevent angiocentric glioma from developing, as it usually arises sporadically in the brain. Prevention is about lowering risk, not eliminating it completely. For many, the focus is on spotting early symptoms of angiocentric glioma—like new seizures or persistent, worsening headaches—and acting quickly to reduce complications. Working closely with a neurology or neuro-oncology team also helps keep day-to-day risks lower.
New unprovoked seizures, behavior or school changes, or headaches that steadily worsen should prompt medical review. Early assessment can reduce complications and stress for families.
If seizures occur with angiocentric glioma, plan for safety around water, heights, cooking, and bathing. Simple steps like supervised swimming and showers instead of baths can prevent injuries.
Keep regular sleep, avoid missed doses, manage fevers promptly, and limit alcohol for adults. These steps can lower the chance of seizure breakthroughs linked to the tumor.
Take anti-seizure medicine exactly as prescribed. Skipping or delaying doses is a common reason seizures return or worsen.
Transmission
Angiocentric glioma is not contagious; it cannot be caught or passed between people through touch, air, or bodily fluids. It arises from DNA changes that occur in certain brain cells after a person is conceived, so the changes are limited to the tumor itself. If you’re wondering how angiocentric glioma is inherited, the short answer is that it typically isn’t—most cases are sporadic and not linked to family history. In other words, there is no genetic transmission of angiocentric glioma from a parent to a child, and having this tumor does not usually increase risk for relatives.
When to test your genes
Consider genetic testing if you have a brain tumor suspected to be angiocentric glioma, especially in children or young adults, to identify targetable changes (like MYB/MYBL1 fusions) that guide surgery and follow‑up. Test tumor tissue first; consider germline testing if there’s early onset, multiple tumors, or family history.
Diagnosis
Angiocentric glioma is usually found when seizures begin or change over time, especially in children and young adults. For many, the first step comes when everyday activities start feeling harder because of repeat seizures or new neurological symptoms. Doctors then use imaging and tissue studies to confirm what’s going on; this stepwise approach is the basis for the diagnosis of Angiocentric glioma. Early and accurate diagnosis can help you plan ahead with confidence.
A clinician asks about seizure patterns, headaches, and any changes in memory, mood, or school/work performance. A focused neurological exam looks for weakness, sensory changes, or vision issues.
MRI creates detailed pictures of the brain to locate the lesion and see how it relates to nearby areas. Angiocentric glioma often appears as a bright spot on T2/FLAIR images within the cortex or just below it.
Special MRI techniques may assess fine details like fiber tracts and potential involvement near critical language or motor areas. This helps plan surgery and anticipate risks.
An electroencephalogram records brain activity to identify where seizures start. Results help link symptoms to the lesion seen on MRI and guide surgical planning.
Stages of Angiocentric glioma
Angiocentric glioma does not have defined progression stages. It’s a slow-growing brain tumor that most often causes seizures rather than spreading, so doctors describe it by its type and grade instead of stages; early symptoms of angiocentric glioma are usually new or hard-to-control seizures. Different tests may be suggested to help confirm the diagnosis and map the tumor’s location. This typically includes brain MRI, sometimes EEG to evaluate seizures, and tissue testing after surgery; follow-up MRI scans are used to monitor for changes.
Outlook and prognosis
Looking at the long-term picture can be helpful. Many people with angiocentric glioma first notice problems like seizures that disrupt school, work, or sleep, and treatment often focuses on getting those under control. With the right support, the future can feel more manageable, especially once a care team lays out a plan. Doctors call this the prognosis—a medical word for likely outcomes.
For most people with angiocentric glioma, the outlook is favorable because this tumor tends to grow slowly and stays in one area. Surgical removal is the main treatment; when the tumor can be fully removed, long-term seizure control is common and survival is excellent, with very low risk of spread to other parts of the brain or body. If only part can be removed, seizures may persist and medicines or additional therapies may be used to reduce them. Early symptoms of angiocentric glioma, such as new-onset focal seizures or episodes of staring and confusion, are a cue to seek prompt evaluation, since early care can make a real difference in daily functioning.
Everyone’s journey looks a little different. Recurrence after complete removal appears uncommon, but follow-up MRI scans are usually recommended for several years to watch for any change. Death from angiocentric glioma is rare based on published reports, though data are limited because the condition is uncommon and often diagnosed in children and young adults. Talk with your doctor about what your personal outlook might look like, including plans for seizure safety, driving rules in your area, and how often to schedule brain imaging and neurology visits.
Long-term effects
For many, the long-term picture centers on seizure control and how the brain area around the tumor heals after treatment. Early symptoms of angiocentric glioma often involve focal seizures, and these can continue, improve, or occasionally return over time. Long-term effects vary widely, and many people do well when the tumor is fully removed and follow-up care is steady. Regular check-ins and brain scans help catch changes early and guide next steps.
Seizures may continue, get milder, or stop after treatment. Many people with angiocentric glioma stay on anti-seizure medicine for a period to prevent breakthroughs. Triggers like poor sleep or missed doses can still bring episodes.
Attention, memory, or processing speed can feel slower for a while. This may affect school, studying, or multitasking at work. Many notice gradual improvement with time and practice.
If the tumor was near language areas, word-finding or fluency may be affected. People with angiocentric glioma may notice trouble keeping up in fast conversations. Speech therapy can support recovery.
Weakness, clumsiness, or numbness can linger if movement or sensory pathways were involved. Fine motor tasks, sports, or balance may feel harder. These often improve with rehab.
How is it to live with Angiocentric glioma?
Living with angiocentric glioma often means navigating uncertainty around seizures, fatigue after seizures, and the anxiety of when the next episode might occur. Daily life can revolve around medication schedules, regular brain imaging, and planning for rest and safety, especially if seizures have not been fully controlled. Many find school, work, and driving need adjustments or temporary limits, and people close to you may take on support roles during appointments or recovery days. With a care team, seizure first-aid plans, and honest communication at home and school or work, most families find a steady rhythm that balances treatment, safety, and normal life.
Treatment and drugs
Treatment for angiocentric glioma focuses on removing the tumor with surgery, since these tumors are usually slow-growing and well defined. Many people do well after complete surgical removal, with seizures and other symptoms often improving once the tumor is out. If a small piece must be left behind because it’s close to vital brain areas, doctors may monitor with regular MRI scans and consider targeted radiation only if it grows or symptoms return. Not every treatment works the same way for every person. Keep track of how you feel, and share this with your care team.
Non-drug treatment
Living with Angiocentric glioma often centers on managing seizures, thinking or language changes, and day-to-day safety. Although medicines are important, many benefit from non-drug care that supports seizure control, recovery after surgery, and learning at school or work. Alongside medicines, non-drug therapies can help you stay active, protect memory and speech, and lower injury risk from seizures. Care usually adjusts over time, especially if early symptoms of Angiocentric glioma were seizures that affect school, driving, or work routines.
Removing the tumor can greatly reduce or stop seizures in many people. Surgeons aim to spare healthy brain tissue while fully removing the lesion. Planning often uses advanced imaging and mapping for safety.
A thin probe delivers heat to destroy tumor tissue through a small opening. Recovery is often quicker than open surgery. Not every tumor location is suitable.
Techniques like brain mapping during surgery locate speech, movement, and memory areas. This helps surgeons avoid critical networks while treating the tumor. It can reduce the chance of lasting deficits.
SEEG pinpoints seizure origins when the picture is unclear. Targeted electrodes map the brain’s electrical activity over days. Results guide surgery or device therapy decisions.
Your genes may have an impact on how drugs work for you
Genes can affect how your body processes antiseizure medicines often used for angiocentric glioma, changing how well they work and the risk of side effects. Pharmacogenetic testing may guide dose choices or drug selection, helping you and your team personalize treatment.
Pharmacological treatments
Living with angiocentric glioma often means managing seizures day to day while planning for surgery or monitoring scans. Medicines mainly aim to control symptoms—especially seizures—and to ease swelling or pressure in the brain. Not everyone responds to the same medication in the same way. There’s no proven drug that reliably shrinks angiocentric glioma itself, so treatment focuses on seizure control and comfort.
Commonly used to control seizures linked to angiocentric glioma with few drug interactions. Many tolerate it well, and it can be used alone or with another anti-seizure medicine.
These sodium‑channel blockers help reduce focal seizures, the most frequent seizure type in angiocentric glioma. They can cause low sodium levels, so blood tests may be checked.
Often chosen when seizures persist or side effects limit other options. It is generally well tolerated but must be increased slowly to reduce the risk of rash.
Useful for broad seizure control when angiocentric glioma causes mixed seizure types. It can affect liver function and blood counts, so regular monitoring is common.
Genetic influences
Research shows that many angiocentric gliomas are driven by a specific DNA change that switches on a growth‑controlling gene inside the tumor cells, often involving a gene called MYB. It’s natural to ask whether family history plays a role. People often ask whether angiocentric glioma is inherited; in nearly all cases, it isn’t, because the change happens only in the tumor and isn’t present in the rest of the body. That means relatives usually aren’t at higher risk, and children are very unlikely to inherit it. Looking at the tumor’s genetic makeup can help doctors confirm angiocentric glioma and distinguish it from other brain tumors, which can guide care and eligibility for clinical trials. Even when the same gene change is found, the tumor’s behavior can vary, so treatment plans are tailored to the person and the tumor’s location.
Is Angiocentric glioma genetic?
Genetics play a central role in angiocentric glioma. Most tumors carry somatic MYB gene alterations that drive growth; these are not inherited. Germline predisposition is rare, so family members typically don’t have increased risk.
Pharmacogenetics—how genetics influence drug effects
Treatment for angiocentric glioma usually centers on surgery, but when medicines are part of care—such as anti-seizure drugs or, less often, chemotherapy—genetics can help shape the plan. Tumor changes, often involving a gene called MYB and occasionally BRAF, may open doors to targeted therapy trials or shape follow-up; if a medicine like temozolomide is considered, a tumor marker called MGMT can help estimate how well it might work. On the personal side, inherited differences can affect how your body handles anti-seizure medicines; for example, certain HLA types are linked to rare but serious skin reactions with carbamazepine and similar drugs, and enzyme gene differences can influence how quickly you break down drugs like phenytoin or clobazam. Not every difference in response is genetic, but recognizing these patterns can reduce side effects and avoid multiple medication changes. Your care team may discuss genetic testing for angiocentric glioma and pharmacogenetic checks before starting or changing medicines, especially if past reactions or family background raise concern.
Interactions with other conditions
Living with seizures from Angiocentric glioma can ripple into other health issues, especially sleep, mood, and learning. Doctors call it a “comorbidity” when two conditions occur together. For many, anxiety or depression may worsen around seizure flares, and poor sleep can make seizures more likely, creating a cycle that’s hard to break. Early symptoms of Angiocentric glioma can mirror common epilepsy disorders, so people may be treated for epilepsy alone at first, and overlapping brain conditions like focal cortical malformations may occasionally be found nearby, which can complicate care. If migraines, ADHD, or autism are also present, attention, school or work performance, and daily routines may need extra support. Medications used for seizures may interact with treatments for other conditions, so coordinated care among neurology, oncology, and primary care helps tailor a plan that fits everything else you’re managing.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described children and teens with new-onset seizures who otherwise seemed healthy, often after a growth spurt or a stressful school term. Families and teachers noticed patterns—spells of staring, brief confusion, or jerks of a limb—followed by long stretches of normal days. Only with modern brain imaging and tissue study did doctors realize that, in some of these cases, the underlying cause was a slow-growing brain tumor now known as angiocentric glioma.
First described in the medical literature as a distinct tumor pattern in the mid-2000s, angiocentric glioma emerged from careful re-review of surgical samples taken from people with long-standing focal epilepsy. Earlier, these tumors had been grouped with other low-grade gliomas because they shared similar slow behavior and location in the brain’s cortex. As more cases were collected, pathologists noticed a signature look under the microscope: tumor cells arranged around small blood vessels in a spoke-like pattern, which helped separate it from other epilepsy-related tumors.
From these first observations, international classification systems began to recognize angiocentric glioma as its own entity. As medical science evolved, reports clarified that the tumor tends to occur in children and young adults, often presenting with seizures that begin in one part of the brain and may secondarily generalize. Surgeons and neurologists linked the history of early, medication-resistant seizures to small, subtly visible cortical lesions on MRI, strengthening the connection between the clinical story and the pathologic diagnosis.
Advances in genetics added another layer. Researchers identified recurrent changes in genes that act like dimmer switches for cell growth and development, supporting why the tumor grows slowly and tends to stay localized. This genetic signature also helped explain why angiocentric glioma behaves differently from faster-growing gliomas, and why complete surgical removal often leads to excellent seizure control.
Over time, descriptions became more precise about imaging features and outcomes. Early reports called it a rare curiosity, but with wider access to high-resolution MRI and better awareness among epilepsy centers, more cases were recognized in people referred for surgery after years of focal seizures. Despite evolving definitions, the core narrative has stayed steady: a slow-growing, surface-based tumor linked to seizures, most often in younger individuals, with a favorable outlook when fully removed.
Knowing the condition’s history helps explain today’s care. The journey—from scattered case notes of unexplained early seizures to a clearly defined diagnosis—has shaped how doctors interpret MRI scans, plan surgery, and counsel families about recovery and long-term seizure control.